drugset / Trial / NCT06289751
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
Phase 2
Recruiting
50 enrolled
Tongji Hospital
Beijing Friendship Hospital · collabGansu Provincial Maternal and Child Health Care Hospital · collabQilu Hospital of Shandong University · collabShengjing Hospital · collabSichuan Cancer Hospital and Research Institute · collabSouthwest Hospital, China · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) · collabTianjin Medical University · collabWest China Second University Hospital · collabWomen's Hospital School Of Medicine Zhejiang University · collabXiangya Hospital of Central South University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.
Timeline
- Start
- 2024-09-03
- Primary completion
- 2026-03-01
- Completion
- 2031-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |